As of 2026-04-13, the Relative Valuation of Innocan Pharma Corp (INNO.CN) is 1.34 CAD. This relative valuation is based on P/E multiples. With the latest stock price at 6.66 CAD, the upside of Innocan Pharma Corp based on Relative Valuation is -79.9%.
The range of the Relative Valuation is (0.08) - 3.56 CAD.
| Range | Selected | |
| Trailing P/E multiples | 0.1x - 2.0x | 0.1x |
| Forward P/E multiples | 7.5x - 12.0x | 9.4x |
| Fair Price | (0.08) - 3.56 | 1.34 |
| Upside | -101.2% - -46.6% | -79.9% |
| Date | P/E |
| 2026-04-10 | -6.57 |
| 2026-04-08 | -6.65 |
| 2026-04-06 | -6.65 |
| 2026-03-31 | -6.65 |
| 2026-03-25 | -6.58 |
| 2026-03-24 | -6.52 |
| 2026-03-20 | -6.64 |
| 2026-03-19 | -6.79 |
| 2026-03-18 | -6.60 |
| 2026-03-17 | -6.23 |
| 2026-03-16 | -6.32 |
| 2026-03-12 | -6.44 |
| 2026-03-10 | -6.57 |
| 2026-03-09 | -6.49 |
| 2026-03-06 | -5.89 |
| 2026-03-03 | -6.09 |
| 2026-03-02 | -6.74 |
| 2026-02-27 | -6.92 |
| 2026-02-26 | -6.84 |
| 2026-02-25 | -6.99 |
| 2026-02-24 | -7.31 |
| 2026-02-23 | -7.75 |
| 2026-02-20 | -8.32 |
| 2026-02-19 | -7.98 |
| 2026-02-18 | -8.06 |
| 2026-02-17 | -8.16 |
| 2026-02-12 | -7.60 |
| 2026-02-11 | -6.35 |
| 2026-02-10 | -7.19 |
| 2026-02-06 | -6.31 |
| 2026-02-05 | -7.22 |
| 2026-02-04 | -7.12 |
| 2026-02-03 | -8.44 |
| 2026-02-02 | -8.98 |
| 2026-01-30 | -9.45 |
| 2026-01-29 | -9.93 |
| 2026-01-28 | -7.34 |
| 2026-01-27 | -6.35 |
| 2026-01-26 | -6.00 |
| 2026-01-22 | -6.99 |
| 2026-01-21 | -7.62 |
| 2026-01-20 | -7.69 |
| 2026-01-16 | -7.98 |
| 2026-01-13 | -8.08 |
| 2026-01-12 | -8.54 |